Sanofi rilzabrutinib Fast Track'd in U.S. for low platelet count

• FDA has granted Fast Track Designation to Sanofi's (NASDAQ:SNY) oral investigational Bruton’s tyrosine kinase inhibitor, rilzabrutinib, for the treatment of immune thrombocytopenia (low blood platelets).
• Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.
• In addition, following positive Phase 1/2 study results, a Phase 3 study evaluating rilzabrutinib for ITP has been initiated.
• https://seekingalpha.com/news/3637353-sanofis-rilzabrutinib-fast-trackd-in-u-s-for-low-platelet-count